ライフサイエンスコーパス: clinical trial

1 recruitment and retention (major expenses in clinical trials).

2 PD1 blockade with pembrolizumab in a phase 2 clinical trial.

3 of a novel therapeutic target and resultant clinical trial.

4 efit-risk assessments during the course of a clinical trial.

5 odelled cohort matched that of a two-country clinical trial.

6 ryngeal gonorrhea in a single-arm, unblinded clinical trial.

7 patients with MRSA bacteremia: a randomized clinical trial.

8 rger National Institutes of Health-sponsored clinical trial.

9 emdesivir treatment in the context of a MERS clinical trial.

10 hemoradiation (NACR) enrolled in a phase III clinical trial.

11 center non-inferiority randomised controlled clinical trial.

12 ease for the Treatment of NAFLD in Children) clinical trial.

13 that are already being collected as part of clinical trials.

14 taining AMA1 alone have been unsuccessful in clinical trials.

15 management of patients and future designs of clinical trials.

16 that FUS-BBB opening treatments have entered clinical trials.

17 cline for improved subject stratification in clinical trials.

18 ing uncertainties can lead to the failure of clinical trials.

19 mpact of this intervention awaits controlled clinical trials.

20 in combination with other drugs in COVID-19 clinical trials.

21 ut are not consistently collected in malaria clinical trials.

22 cations for patient stratification in future clinical trials.

23 ses and failures of hundreds of high-quality clinical trials.

24 c tests and treatments in adequately powered clinical trials.

25 imicrobial resistance, and newer designs for clinical trials.

26 risk stratification, patient monitoring, and clinical trials.

27 ective observational studies and prospective clinical trials.

28 umans contributed to prior failures of human clinical trials.

29 implications, and to increase efficiency in clinical trials.

30 in eyes with diabetic macular edema (DME) in clinical trials.

31 all IRAE rates for comparison with published clinical trials.

32 have been associated with adverse events in clinical trials.

33 identically designed, open-label, randomized clinical trials.

34 ition, this method could be used to optimize clinical trials.

35 stroke have failed to provide protection in clinical trials.

36 tment on SB and colonic ACE2 expression in 3 clinical trials.

37 tisite preclinical studies to translate into clinical trials.

38 re being evaluated in endocrine-resistant BC clinical trials.

39 an transplant recipients was not assessed in clinical trials.

40 line of investigation, with several ongoing clinical trials.

41 ly used in nucleic acid vaccines in multiple clinical trials.

42 ation for the failure of ABCB1 inhibitors in clinical trials.

43 fixed-duration antibiotic therapy randomized clinical trials.

44 cal observations and the results of previous clinical trials.

45 s dosimetry issues and strategies for future clinical trials.

46 ch is of great interest for patient care and clinical trials.

47 n MCF-7:CFR cells than six BET inhibitors in clinical trials.

48 23 (PF-07059013) has advanced to phase 1 clinical trials.

49 ective chemotherapeutics despite a myriad of clinical trials.

50 bone biopsies in both clinical practice and clinical trials.

51 This result might lead to more efficient clinical trials.

52 ed on these findings already being tested in clinical trials.

53 the translation from preclinical studies to clinical trials.

54 a principal challenge will be the design of clinical trials.

55 arring and may be impractical in large-scale clinical trials.

56 future research questions and direct future clinical trials.

57 eing tested in randomized placebo-controlled clinical trials.

58 TC module developed for use in international clinical trials.

59 drugs are essential to support initiation of clinical trials.

60 ns enrolled in large-scale observational and clinical trials.

61 ib and pemigatinib, and all are currently in clinical trials.

62 ng can help optimize and guide the design of clinical trials.

63 B680 is currently being evaluated in phase 1 clinical trials.

64 jects enrolled in placebo groups of TrialNet clinical trials.

65 igh diagnostic accuracy for CAD in 2 phase 3 clinical trials.

66 oth ESCs and iPSCs are already being used in clinical trials.

67 revious findings and in the design of future clinical trials.

68 rther investigation of CRCNet by prospective clinical trials.

69 8 previously did not demonstrate efficacy in clinical trials(3).

70 ble; (2) design more pragmatic and efficient clinical trials; (3) minimize administrative and regulat

71 ons) and in a systematically selected set of clinical trials (accuracy > 84% for predicting statistic

72 The content area was chosen for the robust clinical trial activity in the field.

73 opulations, in properly designed, randomized clinical trials, although data on the long-term durabili

74 s (n = 116) enrolled in 3 phase-3 randomized clinical trials (AMAGINE -1 [Efficacy, Safety, and Withd

75 SLIT was largely used in clinical trials and clinical practice in this last 30 ye

76 KRAS(G12C) inhibitors(3,4) are in phase-I clinical trials and early data show partial responses in

77 as shown excellent safety profile in phase 1 clinical trials and is being evaluated for efficacy and

78 esearch on NIRF nanoprobes has translated to clinical trials and it will further translate to cancer

79 We used data from clinical trials and literature on tuberculosis natural h

80 aluation of treatment response in randomized clinical trials and may guide clinical decision-making i

81 sights into the limited activity of HDACi in clinical trials and offers direction for future approach

82 n this commentary, we review the timeline of clinical trials and regulatory actions of approved immun

83 effectiveness is consistent with efficacy in clinical trials and supports current recommendations tha

84 s isolated from a volunteer in an RTS,S/AS01 clinical trial, and it protects mice from infection by m

85 r TAVI, discuss relevant available data from clinical trials, and highlight procedural implications a

86 fusions, have shown considerable activity in clinical trials, and larotrectinib, entrectinib and pemb

87 e important considerations for the design of clinical trials, and might improve our understanding of

88 ties, nephrology has reported relatively few clinical trials, and most of these are too small to dete

89 ld-based nanodevices are currently tested in clinical trials, and none of them are approved by health

90 ed as development data originating from past clinical trials, and real-world population data as valid

91 care and research, including the conduct of clinical trials, and the clinical research ecosystem wil

92 patient-centric, molecular pathology-driven clinical trial approaches are needed to achieve this goa

93 Seventeen clinical trials are currently registered to inform on th

94 Clinical trials are currently underway to further determ

95 Because prospective clinical trials are lacking, we conducted an open-label,

96 Future clinical trials are necessary to evaluate whether supple

97 Future clinical trials are needed to confirm these findings.

98 epigment vitiliginous skin, and well-powered clinical trials are underway.

99 hes should aim to reduce the failure rate of clinical trials as well as expedite and lower the cost o

100 A randomised phase 3 clinical trial assessing the efficacy and safety of pemb

101 NTS: Multicenter, double-blinded, randomized clinical trial at 20 trauma centers and 39 emergency med

102 ESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial at 39 DRCR Retina Network sites in the US

103 We did an open-label, randomised clinical trial at 57 centres in Brazil.

104 In this meta-analysis of randomized clinical trials, blood pressure lowering with antihypert

105 Several of these inhibitors have advanced to clinical trials, both singly and in combination with oth

106 to assess whether the conclusions drawn from clinical trials can be applied more broadly.

107 gest ways that next-generation genome-driven clinical trials can evolve to accelerate our understandi

108 ated on ART before 3 years of age in a prior clinical trial comparing nevirapine to lopinavir/ritonav

109 promote appropriate oversight and review of clinical trial conduct and results.

110 NG, AND PARTICIPANTS: Open-label, randomized clinical trial conducted at 17 UK hospitals.

111 ESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted at 22 endocrinology practices i

112 IGN, SETTING, AND PARTICIPANTS: A randomized clinical trial conducted at 24 trauma hospitals represen

113 iated, multicenter, single-blind, randomized clinical trial conducted at 5 referral centers for cathe

114 AND PARTICIPANTS: Noninferiority randomized clinical trial conducted from October 26, 2017, through

115 Clinical trial data revealed that PA amino acid substitu

116 Clinical perspective: Clinical trial data show that the efficacy of birch poll

117 Comparison with lumasiran preclinical and clinical trial data suggested she has <2% residual glyco

118 sful drug targets, as measured by historical clinical trial data.

119 rview of the COVID-19 'vaccine landscape', a clinical trials database and a 'living review' that dist

120 is notion has been challenged by large-scale clinical trials demonstrating that, in the modern era of

121 of evolution and radiobiology for in silico clinical trial design allows clinicians to optimize admi

122 armacology, noninvasive neuromodulation, and clinical trial design, we can envision novel therapeutic

123 Novel clinical trial designs offer potential solutions by atte

124 recipients have remained underrepresented in clinical trials, despite representing a rapidly growing

125 ysis and individual trial results from three clinical trials done in Kenya and Uganda.

126 idation dataset consisting of 277 targets of clinical trial drug confirming that our computational ap

127 tions of subjects above/below the 200 pmol/L clinical trial eligibility threshold at the 12-month vis

128 The REMEMBER randomized clinical trial enrolled 850 participants with HIV (CD4 <

129 o biopsy to identify those suitable for NASH clinical trial enrolment.

130 ) extension is a new reporting guideline for clinical trials evaluating interventions with an AI comp

131 the present study provide useful insight for clinical trials evaluating the thermoregulatory outcomes

132 analysis of the ODYSSEY OUTCOMES randomized clinical trial (Evaluation of Cardiovascular Outcomes Af

133 a paucity of randomised, placebo-controlled clinical trial evidence where the primary outcome is an

134 We present evidence that a clinical trial examining the effects of metformin on cog

135 (EXCEL Clinical Trial [EXCEL]; NCT01205776).

136 losteric modulators (NAMs) that have reached clinical trials failed due to lack of efficacy.

137 d first-in-class SHP2 inhibitor currently in clinical trials for cancer.

138 ommendations for the conduct and analysis of clinical trials for cardiovascular disease and heart fai

139 s therapeutic treatment options, and ongoing clinical trials for functional mitral regurgitation.

140 eurotrophic factor (CNTF) has been tested in clinical trials for human retinal degeneration due to it

141 Although the number of clinical trials for patients with COVID-19 is increasing

142 Although clinical trials for Stargardt are currently underway, th

143 ears, there has been an increasing number of clinical trials for the treatment of nonalcoholic steato

144 as well as a compendium of active, enrolling clinical trials for this population.

145 r diseases and purposes such as in designing clinical trials for unmasking the maximum benefits and m

146 In total, 606 clinical trials forming 220 distinct development traject

147 ave helped to shift attrition rates in early clinical trials from poor exposure to drug safety concer

148 As clinical trials get under way in specific genetic forms

149 brary, AMED, SPORTDiscus, Web of Science and Clinical Trials.gov from their earliest records to Janua

150 AIDS Clinical Trials Group A5312 is a Phase 2A, open-label tr

151 ssed pre/post-INSTI weight changes from AIDS Clinical Trials Group participants (A5001 and A5322).

152 Similarly, fewer clinical trials have been completed in PDAC (n = 608) co

153 Randomized clinical trials have demonstrated that catheter ablation

154 Numerous randomized clinical trials have demonstrated the superiority of thi

155 Two large clinical trials have shown a reduced rate of breast canc

156 Though several hundred clinical trials have tested immune-based approaches in c

157 options for metastatic UM are limited, with clinical trials having little impact.

158 In clinical trials, HCV salvage treatment with Sofosbuvir/V

159 The RECOVERY clinical trial, however, revealed that treatment with de

160 ntly, a peptidomimetic inhibitor has entered clinical trial; however, small-molecule orally available

161 This prospective study (Verona Pilot Study, clinical trial identification: 2015/1238) included women

162 dolescent Acquired Immunodeficiency Syndrome Clinical Trials [IMPAACT] P1060); 183 age-matched, expos

163 TS: A parallel-group, randomized multicenter clinical trial in 26 centers across Germany was conducte

164 We did the first randomised clinical trial in the USA of extracorporeal membrane oxy

165 Six-month double-blind, randomized clinical trial in which participants with PAD were rando

166 d medical history when designing prospective clinical trials in an attempt to minimize data loss.

167 rs and scientists have initiated hundreds of clinical trials in an expedited effort to understand, pr

168 lockade (ICB) in melanoma and other cancers, clinical trials in breast cancer have reported low respo

169 are currently being evaluated in early phase clinical trials in children with high-risk MYCN-driven d

170 lls (PBMC) RNA from subjects enrolled in the Clinical Trials in Organ Transplantation-09 study in whi

171 We pooled genital sub-studies from 2 clinical trials in this area.

172 er, noninferiority, point-of-care randomized clinical trial including adults hospitalized with gram-n

173 tes for human evaluation, and to use dynamic clinical trial interventions with liquid biopsies to del

174 operimetry is a sensitive outcome measure in clinical trials investigating new treatments for degener

175 At least 2 prospective clinical trials involving (177)Lu-PSMA agents are under

176 g the molecular findings and accessing drugs/clinical trials is challenging.

177 Testing potential therapies in clinical trials is hampered by our inability to distingu

178 er, the efficacy of this treatment in recent clinical trials is moderate compared with results seen i

179 drug development, testing and progression to clinical trials is overwhelmingly expensive.

180 dition, an overview of ongoing and completed clinical trials is provided.

181 in the context of cancer and mucosal cancer clinical trials is provided.

182 igosertib, an anti-cancer agent in phase III clinical trials, kills cancer cells by destabilizing mic

183 , including recent evidence from 2 phase III clinical trials (LEAP 1 and LEAP 2), and discusses its p

184 er studies evaluated in this review included clinical trials, meta-analyses, and retrospective analys

185 anuary 2015 through June 2020 for randomized clinical trials, meta-analyses, systematic reviews, and

186 Future clinical trials must focus on patients who really need a

187 e aim of this prospective single-institution clinical trial (NCT02002455) was to evaluate the potenti

188 treatment approaches, we designed a National Clinical Trials Network (NCTN) study to improve outcomes

189 ung-MAP (S1400) was done within the National Clinical Trials Network of the NCI using a public-privat

190 We conducted a phase 1, open-label clinical trial (no.

191 The recently halted HVTN702 clinical trial not only further stresses the challenge t

192 With Phase I/II clinical trials now underway using first-generation vacc

193 ework is a structured approach to aligning a clinical trial objective with the study design, includin

194 er, double-blind, parallel-group, randomized clinical trial of 775 adult patients at increased risk o

195 re, we report the first open-label, phase Ib clinical trial of a personalized neoantigen-based vaccin

196 couragement, she elected to participate in a clinical trial of an investigational drug that is now wi

197 However, a recent placebo-controlled clinical trial of AV-101 in depression found negative re

198 A recent clinical trial of carfilzomib (a second-generation irrev

199 In a clinical trial of cerebral palsy, the level of plasma in

200 rom both preclinical mouse experiments and a clinical trial of FMT to validate our theoretical framew

201 owing withdrawal from immunosuppression in a clinical trial of kidney transplant recipients.

202 arnessing the power of a multi-site, ongoing clinical trial of lithium monotherapy.

203 In a cohort of infants enrolled in a clinical trial of maternal influenza vaccination, we est

204 gnosis (N = 66) participated in a randomized clinical trial of prolonged exposure therapy (n = 36) ve

205 gG antibody responses in sera from a phase 2 clinical trial of Takeda's live-attenuated tetravalent d

206 We conducted a randomized clinical trial of text messaging (TM) versus no text mes

207 enter, parallel-group, open-label randomized clinical trial of upper airway surgery vs ongoing medica

208 of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests,

209 AS is on the horizon and the first data from clinical trials of autonomous RAS in urology are being p

210 ubjects who experienced virologic failure in clinical trials of direct-acting antivirals.

211 Nonetheless, human clinical trials of iPSC-derived cells have not previousl

212 Experience from clinical trials of novel therapies has provided a new pe

213 matic review and meta-analysis of randomized clinical trials of patients with primarily noncancer ill

214 The success of clinical trials of selective B-cell depletion in patient

215 e F3 or F4) were enrolled in 4 multinational clinical trials of simtuzumab and selonsertib.

216 ure, and highlights the results of phase III clinical trials of therapies targeting inflammatory proc

217 in this review, of which 12 were randomized clinical trials of therapy that included 3074 patients,

218 Clinical trials of typhoid conjugate vaccine (TCV) are o

219 ctivation in tumor progression, results from clinical trials of various AKT inhibitors remain subopti

220 on-carriers that may be considered as future clinical trial outcomes.

221 Additional safety data from clinical trials outside of childhood epilepsy syndromes

222 icalTrials.gov, NCT03271307, and Pan African Clinical Trials, PACTR201711002697316.

223 r data and safety monitoring boards, protect clinical trial participants by conducting benefit-risk a

224 In this parallel-group, double-blind clinical trial, participants were randomized to receive

225 Materials and Methods In this pilot clinical trial, participants with HCC scheduled for subl

226 In an open label clinical trials, participants with ASD were administered

227 le remission rates of approximately 40% in a clinical trial population.

228 utine inclusion of diffusion analyses within clinical trials principally as an additional measure to

229 tatement aims to improve the completeness of clinical trial protocol reporting by providing evidence-

230 bjective it remains central to diagnosis and clinical trial protocols and is crucial for the evaluati

231 Observational studies, clinical trials, qualitative studies, and case series wi

232 as performed to identify eligible randomized clinical trials (RCTs) reporting on the changes in GT an

233 clinical practice and a large cost-saving in clinical trial recruitment.

234 South African National Clinical Trial Register (DOH-27-0913-4183).

235 This study is registered with the EU Clinical Trials Register (EudraCT 2010-022134-89).

236 ross-sectional analysis of all heart failure clinical trials registered on ClinicalTrials.gov with at

237 Study registered with Australian New Zealand Clinical Trial Registry (ACTRN 12613001368729).

238 Chinese Clinical Trial Registry ChiCTR1800015584.

239 This trial was preregistered at the European Clinical Trial Registry, EudraCT#2016-000891-54 (2016-10

240 tered with the National Institutes of Health Clinical Trial registry, NCT02895269.

241 y registered with the Australian New Zealand Clinical Trials Registry (ACTRN12614000936628).

242 This trial was registered at the Clinical Trials Registry of India as CTRI/2018/04/012957

243 Australian New Zealand Clinical Trials Registry, identifier ACTRN12611000402943

244 onpersistence) with respect to evidence from clinical trials remains a significant barrier to optimiz

245 Recent clinical trial results showed that transcatheter aortic

246 Unfortunately, clinical trial results with HDACi have thus far been dis

247 To shed light on the integrity of clinical trial results, this paper systematically analyz

248 The clinical trials should be on the same brain area for the

249 Future clinical trials should use individualized therapies (e.g

250 A phase I clinical trial showed that the combination of CB-839 and

251 focused on current dosimetric approaches for clinical trials, strategies under development that would

252 tivity analyses using different estimates of clinical trial success rates, preclinical expenditures,

253 Randomized clinical trials support the efficacy of MDMA in the trea

254 However, clinical trials targeting IL-17A in uveitis were not suc

255 critical regulator of lipid metabolism, and clinical trials targeting PCSK9 reduce cardiovascular di

256 report negative results on a randomized clinical trial testing the combination of apremilast, a

257 Peripheral Artery Disease) was a randomized clinical trial that assigned patients with peripheral ar

258 These discoveries have led to numerous clinical trials that have aimed to reduce the levels of

259 the most recent and relevant preclinical and clinical trials that have tested ASO therapeutics in pol

260 clinical practice, opportunities for virtual clinical trials, the use of artificial intelligence to s

261 In this study, we performed a phase 1 clinical trial to assess the safety and feasibility of f

262 This is a randomized and double-blind clinical trial to evaluate the efficacy of miltefosine c

263 Label, 2x2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs Vit

264 the basis of the above, we suggest designing clinical trials to assess the promising potential of suc

265 ons can range from discovery science through clinical trials to clinical practice.

266 Clinical trials to date have been largely unsuccessful i

267 It was further applied to two phase I clinical trials to evaluate potential biomarkers for OCT

268 conducted a meta-analysis of ten randomized clinical trials to evaluate the efficacy and safety of D

269 atients in two ongoing, multicentre, phase 1 clinical trials to evaluate the safety and antileukaemic

270 of Down syndrome (DS), translation to human clinical trials to improve cognition in individuals with

271 ssessment of the AI system paves the way for clinical trials to improve the accuracy and efficiency o

272 es for diagnosis and management, and ongoing clinical trials to provide expanded treatment options.

273 nd smoking history are often used in current clinical trials to select patients for deintensification

274 1 inhibitor, currently completed phase 1b of clinical trials, to be a potential treatment for IPF.

275 cines and monoclonal antibodies currently in clinical trials, understanding national trends in bronch

276 Cancer Research UK, MRC Clinical Trials Unit, and Canadian Cancer Society.

277 Clinical trials using adult stem cells to regenerate dam

278 These findings have led to the initiation of clinical trials using approved drugs that target the gen

279 Our findings strongly support clinical trials using L-AZM as a novel and clinically re

280 Promising preclinical results have prompted clinical trials using MSC-based therapy in SOT.

281 eading to the initiation of proof-of-concept clinical trials using senolytics for several endocrine a

282 Clinical trials using whole-sporozoite-based vaccination

283 IPANTS: A multicenter, pragmatic, randomized clinical trial was conducted in 65 ICUs in the United Ki

284 The hypothesis of this randomized controlled clinical trial was that local application of enamel matr

285 goal of this 12-month randomized controlled clinical trial was to compare three-dimensional (3D) rid

286 from an intrapartum azithromycin randomized clinical trial, we found that children whose mothers had

287 In this multicentre double-blind randomized clinical trial, we investigated the effects of oral chol

288 Fourteen randomized clinical trials were eligible for inclusion (96 158 part

289 No clinical trials were identified.

290 Patients (n=301) from 3 HFpEF clinical trials were studied.

291 bling the recruitment process for the target clinical trial, which then can be used for augmenting th

292 mized 40 SCZ non-smokers into a double-blind clinical trial with four groups: placebo, 5 mg/d, 10 mg/

293 Clinical trials with anti-tau drugs will need to target

294 In clinical trials with early Alzheimer's patients, adminis

295 However, clinical trials with expanded T(regs) in T1D and solid-o

296 These molecules are undergoing clinical trials with promising results in renal and othe

297 ave been studied in several short-term human clinical trials, with conflicting results.

298 nd Na(V)1.8-specific blockers have undergone clinical trials, with others in preclinical development,

299 ndidate HIV interventions for men advance to clinical trials without preclinical efficacy data, due p

300 The criteria of the Prostate Cancer Clinical Trials Working Group (PCWG2) include clinical a